Momenta Pharmaceuticals, Inc. (MNTA)
(Delayed Data from NSDQ)
$14.57 USD
+0.53 (3.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $14.58 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[MNTA]
Reports for Purchase
Showing records 1 - 20 ( 202 total )
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Johnson - Johnson to Acquire Momenta for $6.5B; Downgrade to Neutral, Price Target to $52.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Assets Advancing With Key Readouts for M254 and Nipocalimab Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Updating Model for Recent Developments in Anti-FcRn mAb Space; Reiterate Buy, Increase PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Nipocalimab Shows Monthly Is Plenty Good with Vivacity Success; Reiterate Buy, PT up to $46
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Key Readouts Upcoming Highlight Richness of the Pipeline; Reiterate Buy and Raise PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Vivacity-MG Still on Track Despite Covid-19, Though Other Studies Not Surprisingly Slowed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Biomedical and Genetics
KOL Perspectives on FcRn''s for the Treatment of Myasthenia Gravis
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department